# 3D-Printed PLDLA–TMC/PEG 400 Vascular Scaffolds with a Poly(hexamethylene Biguanide) Antibacterial Coating

**Authors:** Monique M. Munhoz, Flavia Pedrini, Cecilia T. de Barros, Maria Eduarda Dias, Camilla Fanelli, Irene L. Noronha, Daniel Komatsu, Eliana A. de R. Duek, Moema de A. Hausen

PMC · DOI: 10.3390/pharmaceutics18020204 · 2026-02-04

## TL;DR

This study created 3D-printed vascular scaffolds with improved strength and antibacterial properties for better tissue integration and infection prevention.

## Contribution

A novel 3D-printed vascular scaffold with optimized mechanical and antibacterial properties using PLDLA–TMC and PHMB coatings.

## Key findings

- Adding 2% PEG increased scaffold tensile strength and elasticity.
- 6% PHMB coating provided sustained antimicrobial release and good biocompatibility.
- Scaffolds supported organized cell adhesion and proliferation in co-cultures.

## Abstract

Background: Synthetic vascular scaffolds often exhibit limited mechanical performance and low hydrophilicity, which compromise early vascular integration and increase susceptibility to bacterial colonization. This study developed 3D-printed scaffolds based on poly(L-co-D,L-lactide)–poly(trimethylene carbonate) (PLDLA–TMC) with polyethylene glycol 400 (PEG) to modulate mechanical and interfacial properties and coated with poly(hexamethylene biguanide) (PHMB) to confer antibacterial activity. Methods: PLDLA–TMC scaffolds modified with PEG 400 and coated with PHMB were prepared and systematically characterized to assess their structural, thermal, mechanical, and antimicrobial properties. PHMB coatings (3%, 6%, and 12% w/w in hydroxypropyl methylcellulose, HPMC) were applied and evaluated for drug release, cytotoxicity, and activity against Staphylococcus aureus. Biocompatibility was tested in an endothelial cell and myoblast co-culture. Results: Incorporation of 2% PEG increased the tensile strength from 0.14 ± 0.10 MPa for scaffolds containing 0.5% PEG to 0.79 ± 0.12 MPa and promotes a more elastic scaffold behavior. PHMB at 12% caused cytotoxicity (7.70 ± 0.37% cell viability). The 3% PHMB coating produced a 12.5 ± 0.1 mm inhibition zone but exhibited burst release within 1 h, whereas the 6% coating maintained cell viability (72.95 ± 1.10%), produced a 13.1 ± 0.2 mm inhibition zone, and provided sustained antimicrobial release over 7 days. Scaffolds supported organized adhesion and proliferation of endothelial cells and myoblasts. Conclusions: 3D-printed PLDLA–TMC scaffolds containing 2% PEG and coated with 6% PHMB combined improved mechanical performance, sustained antimicrobial release, antibacterial activity, and biocompatibility in an in vitro vascular model.

## Linked entities

- **Chemicals:** polyethylene glycol 400 (PubChem CID 174), poly(hexamethylene biguanide) (PubChem CID 57345804), hydroxypropyl methylcellulose (PubChem CID 57503849)

## Full-text entities

- **Diseases:** stenosis (MESH:D003251), injury to (MESH:D014947), inflammatory (MESH:D007249), vascular diseases (MESH:D014652), vessel obstruction (MESH:C536223), peripheral artery disease (MESH:D058729), thrombosis (MESH:D013927), deaths (MESH:D003643), Cardiovascular diseases (MESH:D002318), infections (MESH:D007239), ischemic heart disease (MESH:D017202), Cytotoxicity (MESH:D064420)
- **Chemicals:** water (MESH:D014867), PHMB (MESH:C031233), DTG (MESH:C562325), PEG (MESH:C000595213), gentamicin (MESH:D005839), HCl (MESH:D006851), NaOH (MESH:D012972), TMC (MESH:C443643), Sn(Oct)2 (MESH:C419565), methanol (MESH:D000432), chitosan (MESH:D048271), Formazan (MESH:D005562), PEG (MESH:D011092), nitrogen (MESH:D009584), poly(trimethylene carbonate) (MESH:C059299), ester (MESH:D004952), HPMC (MESH:D065347), agar (MESH:D000362), Coomassie Brilliant Blue (MESH:C004692), Streptomycin (MESH:D013307), Polymer (MESH:D011108), polystyrene (MESH:D011137), lactide (MESH:C091880), poly(lactic acid) (MESH:C033616), chloroform (MESH:D002725), paraformaldehyde (MESH:C003043), THF (MESH:C018674), PBS (MESH:D007854), polyurethane (MESH:D011140), DAPI (MESH:C007293), DMSO (MESH:D004121), fexofenadine (MESH:C093230), Hinton (-), Tg (MESH:D013866), Penicillin (MESH:D010406), Alexa Fluor 647 (MESH:C569686), polyester (MESH:D011091), MTT (MESH:C070243), oil (MESH:D009821), Alexa Fluor 488 (MESH:C000711379)
- **Species:** Hyphomicrobium sp. PMC (species) [taxon 161967], Escherichia coli (E. coli, species) [taxon 562], Pseudomonas aeruginosa (species) [taxon 287], Staphylococcus aureus (species) [taxon 1280], Staphylococcus epidermidis (species) [taxon 1282], Homo sapiens (human, species) [taxon 9606]
- **Mutations:** K100M
- **Cell lines:** Dashed line — Mus musculus (Mouse), Adenoma of the mouse pulmonary system, Cancer cell line (CVCL_5V03), ATCC 25923 — Homo sapiens (Human), Lung adenocarcinoma, Cancer cell line (CVCL_0023)

## Figures

14 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12944201/full.md

---
Source: https://tomesphere.com/paper/PMC12944201